Objectively evaluating disease activity in autoimmune bullous disease (AIBD) is important in terms of the clinical assessment of patients and as an outcome measure for clinical trials. Measures need to be general enough to capture the issues specific to each of the bullous dermatoses but specific enough to capture any changes to disease status for a patient. Different tools have been put forward over the last 15 years, but presently the Autoimmune Bullous Skin Disorder Intensity Score and Pemphigus Disease Area Index seem to be the most promising tools to assess disease activity in AIBD.